Search clinical trials for: Melphalan

Total 817 results

Delcath Systems Inc.
National Cancer Institute (NCI)

Completed

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Metastatic Cancer | Intraocular Melanoma | Melanoma (Skin)

United States
Shire

Completed

Study of SHP620 (Maribavir) in Healthy Adults

Cytomegalovirus (CMV)

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
St. Anna Kinderkrebsforschung

Completed

Allogeneic Stem Cell Transplantation for Children With CML

Chronic Myeloid Leukemia

Austria, Czechia, Italy
Celgene

Completed

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM (ARUMM)

Multiple Myeloma

France, Italy, Spain, Belgium, Greece
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma (aMILs)

Multiple Myeloma

United States
Intergroupe Francophone du Myelome

Completed

Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone

Myeloma

France
Memorial Sloan Kettering Cancer Center

Terminated

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Non-Malignant Hematologic Disorders

United States
Oncopeptides AB

Approved for marketing

Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma (sEAPort)

Relapsed and/or Refractory Multiple Myeloma

United States
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
Juvabis AG
Innovative Medicines Initiative

Completed

First-In-Human Study of Apramycin

Healthy Volunteers

Germany
Weill Medical College of Cornell University

Completed

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

United States
M.D. Anderson Cancer Center

Completed

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Lymphoma | Diffuse Large Cell Lymphoma

United States
University of Chicago

Completed

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

Lymphoma | Leukemia | Multiple Myeloma | Myelodysplastic Syndrome

United States
Institut Cancerologie de l'Ouest

Terminated

Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse (TOMMY)

Multiple Myeloma in Relapse

France
M.D. Anderson Cancer Center

Completed

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Lymphoma | Disorder Related to Bone Marrow Transplantation

United States
University of Southampton
NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation... and other collaborators

Terminated

High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant (AntiCD-66)

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | CD20-Positive Neoplastic Cells Present | Refractory Mature B-Cell Non-Hodgkin Lymphoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Completed

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
Samsung Medical Center

Unknown

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) (VIDL+ASCT)

Extranodal NK-T-Cell Lymphoma

Korea, Republic of
Washington University School of Medicine

Terminated

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia

United States
St. Jude Children's Research Hospital
CURE Childhood Cancer, Inc.

Completed

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Melanoma | Lymphoma | Renal Cell Carcinoma | Ewing Sarcoma | Rhabdoid Tumor | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Germ Cell Tumor | Gastrointestinal Tumor | Hepatic Tumor | Clear Cell Carcinoma | Non-rhabdomyosarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
University of Miami
United States Department of Defense

Completed

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

Multiple Sclerosis

United States
Boston Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Amyloidosis

United States
M.D. Anderson Cancer Center
Cephalon

Completed

Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Myeloma

United States
M.D. Anderson Cancer Center

Completed

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Lymphoma | Leukemia

United States
Boston Medical Center

Completed

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
University Hospital, Lille
Amgen

Unknown

Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma (IFM2012-03)

Multiple Myeloma

France
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Impel Pharmaceuticals

Completed

Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal (THOR201)

Parkinson's Disease

Australia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Weill Medical College of Cornell University

Completed

Intra-arterial Chemotherapy for Spinal Metastases (SIAC)

Spinal Diseases | Spinal Metastases | Spinal Tumors

United States
Jonsson Comprehensive Cancer Center
Novartis Pharmaceuticals

Withdrawn

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present

United States
Louisiana State University Health Sciences Center...

Terminated

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Breast Cancer

United States
University of Arkansas
Bristol-Myers Squibb; Altor BioScience

Withdrawn

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Multiple Myeloma

United States
University of California, San Francisco

Terminated

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma (DMV)

Multiple Myeloma | Patient Participation

United States
Federal State Budgetary Institution, Pulmonology...
Moscow State University of Medicine and Dentistry; Medsi Clinic #1, Moscow

Unknown

Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia (MICOV)

COVID-19 | Viral Pneumonia

Russian Federation
U.S. Army Medical Research and Development Command
Naval Medical Research Center

Withdrawn

A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI) (ECG-CHMI)

Plasmodium Falciparum
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Myeloma

United States
Acrotech Biopharma Inc.
Clinipace Worldwide; Beckloff Associates, Inc.; Kansas City Bioanalytical Laboratories

Completed

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Myeloma

United States
University of California, San Francisco

Terminated

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Retinoblastoma | Advanced Intra-Ocular Retinoblastoma

United States
St. Jude Children's Research Hospital

Completed

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Hodgkin Lymphoma | Myelodysplastic Syndrome (MDS) | Leukemia, Acute Lymphocytic (ALL) | Juvenile Myelomonocytic Leukemia (JMML) | Leukemia, Myeloid, Acute(AML) | Leukemia, Myeloid, Chronic(CML) | Hemoglobinuria, Paroxysmal Nocturnal (PNH) | Lymphoma, Non-Hodgkin (NHL)

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Amyloidosis | Light Chain Deposition Disease (LCDD or MIDD) | Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) | Monoclonal Immunoglobulin Deposition Disease (MIDD)

United States
NCIC Clinical Trials Group

Completed

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada, United States
M.D. Anderson Cancer Center

Completed

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Leukemia | Hematologic Malignancies | Blood Stem Cell Transplant Failure

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma

United States
Chun-Yao Huang

Unknown

Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction

Heart Failure | Atrial Fibrillation | Ivabradine

Taiwan

Search clinical trials for: Melphalan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations